Risk and Benefit Profile With Concurrent Nonsteroidal Anti-Inflammatory Drugs and Direct Oral Anticoagulants Following Total Knee Arthroplasty
The Journal of Arthroplasty · 2026-06
DOI: 10.1016/j.arth.2026.06.016 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Arthroplasty, 2026-06. Verfasst von Benjamin R Paul und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedic Surgery, Mayo Clinic, Phoenix, Arizona; Creighton University School of Medicine, Phoenix, Arizona. Die Arbeit nennt 45 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly prescribed after total knee arthroplasty (TKA) for analgesia and inflammation control in conjunction with direct oral anticoagulants (DOACs) for venous thromboembolism (VTE) prophylaxis in high-risk patients. In non-orthopaedic populations, concurrent NSAID-anticoagulant increases bleeding risk, but post-TKA safety data remain limited. METHODS Using a national claims database (2010 to 2023), we identified patients undergoing primary TKA who received DOAC-only VTE prophylaxis for ≥ three days. Patients co-prescribed NSAIDs were propensity score-matched 1:3 to DOAC-only patients based on demographics, comorbidities, and preoperative anticoagulant use. The matched cohort included 12,733 patients who received DOAC plus NSAID therapy and 37,127 who received DOAC alone. Outcomes included 90-day medical and surgical complications, two-year implant-related complications, and arthrofibrosis-associated outcomes. Subanalyses evaluated outcomes by NSAID type and prescription duration. RESULTS Combination therapy was associated with increased wound dehiscence (odds ratio (OR) 1.49, 95% confidence interval (CI) 1.20 to 1.87), surgical site infection (OR 1.71 [1.25 to 2.34]), and periprosthetic joint infection (OR 1.24 [1.01 to 1.52]), without differences in 90-day bleeding events (P > 0.05). At two years, NSAID plus DOAC therapy was associated with higher revision risk (OR 1.52 [1.13 to 2.05]), but lower arthrofibrosis (OR 0.92 [0.86 to 0.98]) and manipulation under-anesthesia rates (OR 0.69 [0.62 to 0.77]). Subgroup analyses demonstrated that celecoxib was associated with higher rates of wound dehiscence, surgical site infection, and blood loss anemia, while ibuprofen was associated with an increased risk of surgical site infection. CONCLUSION Patients who received concurrent NSAIDs with DOAC prophylaxis following TKA had higher rates of wound complications, infection, and all-cause revision, despite lower rates of arthrofibrosis-related outcomes. These findings demonstrate a clinically relevant trade-off and emphasize the importance of patient-specific risk stratification and cautious NSAID selection when used concurrently with DOAC therapy after TKA.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Orthopaedic Surgery, Mayo Clinic, Phoenix, Arizona; Creighton University School of Medicine, Phoenix, Arizona.
- Department of Orthopaedic Surgery, Mayo Clinic, Phoenix, Arizona.
- Creighton University School of Medicine, Phoenix, Arizona.
Zitieren
APA
Paul, B. R., Verhey, J. T., Haak, G. M., Braithwaite, C. L., Tarabichi, S., Christopher, Z. K., Spangehl, M. J., & Bingham, J. S. (2026). Risk and Benefit Profile With Concurrent Nonsteroidal Anti-Inflammatory Drugs and Direct Oral Anticoagulants Following Total Knee Arthroplasty. The Journal of Arthroplasty. https://doi.org/10.1016/j.arth.2026.06.016
Vancouver
Paul BR, Verhey JT, Haak GM, Braithwaite CL, Tarabichi S, Christopher ZK, et al. Risk and Benefit Profile With Concurrent Nonsteroidal Anti-Inflammatory Drugs and Direct Oral Anticoagulants Following Total Knee Arthroplasty. The Journal of Arthroplasty. 2026. doi:10.1016/j.arth.2026.06.016
BibTeX
@article{Paul2026,
author = {Paul, Benjamin R and Verhey, Jens T and Haak, Grace M and Braithwaite, Collin L and Tarabichi, Saad and Christopher, Zachary K and Spangehl, Mark J and Bingham, Joshua S},
title = {Risk and Benefit Profile With Concurrent Nonsteroidal Anti-Inflammatory Drugs and Direct Oral Anticoagulants Following Total Knee Arthroplasty},
journal = {The Journal of Arthroplasty},
year = {2026},
doi = {10.1016/j.arth.2026.06.016}
}
EUVIMED